LON:NIOX

NIOX Group Interim Earnings Results & Report

NIOX Group logo
GBX 63 +1.00 (+1.61%)
As of 06:23 AM Eastern

NIOX Group reported Interim earnings on September 30, 2025. The company reported EPS of GBX 1.43.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

NIOX Group EPS Results

Actual EPS
GBX 1.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NIOX Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

NIOX Group Interim Earnings FAQ

NIOX Group (LON:NIOX) reported earnings of GBX 1.43 per share for Interim. The report was announced on Tuesday, September 30, 2025.

NIOX Group Earnings Headlines

3 British Healthcare Stocks With Revenue Growth Up To 13%
Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
British Healthcare Stocks To Watch In November 2026
NIOX Group (LON:NIOX) Stock: Insider Ian Johnson Sells 193,361 Shares
See More NIOX Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NIOX Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NIOX Group and other key companies, straight to your email.

About NIOX Group

NIOX Group (LON:NIOX) is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries. NIOX is committed to enabling more precise and personalised care for patients with respiratory conditions, with a focus on quality, innovation, and scientific excellence.

View NIOX Group Profile